Prothena CorpPRTA
About: Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Employees: 173
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
46% more call options, than puts
Call options by funds: $3.01M | Put options by funds: $2.06M
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
7% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 45
1% more funds holding
Funds holding: 159 [Q2] → 160 (+1) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
1.49% less ownership
Funds ownership: 96.54% [Q2] → 95.05% (-1.49%) [Q3]
20% less capital invested
Capital invested by funds: $1.07B [Q2] → $858M (-$213M) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 109 / 339 met price target | 249%upside $48 | Buy Reiterated | 20 Dec 2024 |
Chardan Capital Rudy Li 0% 1-year accuracy 0 / 4 met price target | 190%upside $40 | Buy Initiated | 20 Dec 2024 |
B of A Securities Tazeen Ahmad 21% 1-year accuracy 6 / 29 met price target | 60%upside $22 | Neutral Maintained | 19 Dec 2024 |
Financial journalist opinion
